VECTEUR RECOMBINÉ POUR SUPPRIMER LA PROLIFÉRATION DE CELLULES DE PAPILLOMAVIRUS HUMAIN COMPRENANT LE GÈNE DU POLYPEPTIDE ACTIVANT L'ADÉNYLATE CYCLASE 1 (PITUITAIRE) ET COMPOSITION PHARMACEUTIQUE POUR TRAITER LE PAPILLOMAVIRUS HUMAIN
The present invention relates to a cervical cancer therapeutic agent comprising a recombinant vector containing a gene that encodes adenylate cyclase activating polypeptide 1 (pituitary) (ADCYAP1). The use of the recombinant vector and a pharmaceutical composition comprising the recombinant vector can prevent or treat cervical cancer by inhibiting the proliferation of cervical cancer cells.